AB-3PRGD2

AB-3PRGD2 is a radiotherapeutic agent targeting integrin αvβ3. AB-3PRGD2 shows improved tumor uptake and prolonged tumor retention, leading to significantly enhanced tumor growth suppression. AB-3PRGD2 can remodel the tumor immune microenvironment by upregulating PD-L1 expression and increasing tumor-infiltrating CD8+ T cells[1].

Product Specifications

CAS Number

[2416165-76-7]

UNSPSC

12352005

Target

Integrin; PD-1/PD-L1

Related Pathways

Cytoskeleton; Immunology/Inflammation

Field of Research

Cancer

Smiles

OC(CN(CCN(CCN(CC1)CC(O)=O)CC(O)=O)CCN1CC(N[C@H](C(N[C@@H](C(O)=O)CCCCNC(CCCC2=CC=C(C=C2)I)=O)=O)CSC3C(N(C(C3)=O)CCCCCC(NCCOCCOCCOCCOCCC(N[C@H](C(NCCOCCOCCOCCOCCC(NCCCC[C@@H]4NC([C@H](NC([C@@H](NC(CNC([C@@H](NC4=O)CCCNC(N)=N)=O)=O)CC(O)=O)=O)CC5=CC=CC=C5)=O)=O)=O)CCC(NCCOCCOCCOCCOCCC(NCCCC[C@@H]6NC([C@H](NC([C@@H](NC(CNC([C@@H](NC6=O)CCCNC(N)=N)=O)=O)CC(O)=O)=O)CC7=CC=CC=C7)=O)=O)=O)=O)=O)=O)=O)=O

Molecular Formula

C137H215IN30O45S

Molecular Weight

3161.32

References & Citations

[1]Shi J, et al. Nuclear imaging of PD-L1 expression promotes the synergistic antitumor efficacy of targeted radionuclide therapy and immune checkpoint blockade. Eur J Nucl Med Mol Imaging. 2025 Feb;52 (3) :955-969.